Both in Biotechnology
Protara Therapeutics vs Coherus Oncology
Over the past year TARA returned −52.9% and CHRS returned −49.6%; their daily moves had a correlation of 0.27.
TARA −52.9% CHRS −49.6%Growth of $1, one year, split-adjusted
| Metric | TARA | CHRS |
|---|---|---|
| Price | $2.41 | $0.8056 |
| Market cap | $142.4M | $124.5M |
| Today | 0.00% | +7.50% |
| 1 month | −8.4% | −28.1% |
| 6 months | −55.5% | −55.0% |
| Year to date | −54.8% | −43.3% |
| 1 year | −53.5% | −52.0% |
| Revenue growth (YoY) | — | +39.5% |
| Gross margin | — | 70.4% |
| Net margin | — | −144.2% |
| P/E (TTM) | — | — |
| Price / sales | — | 2.4× |
| Net cash | $142.5M | $68.1M |
| Dividend yield | — | — |
| Volatility (60d) | 49.0% | 94.6% |
| Short % of float | 11.5% | 9.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).